Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.58 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2573318 | 0.89 | HRH4 (0.49) | HRH4CHEK1CHEK2HRH3KDR | |
| SCHEMBL3819188 | 0.81 | SMN1; SMN2 (0.51) | HRH4CHEK1HRH3KDRHRH2 | |
| SCHEMBL2567649 | 0.80 | SMN1; SMN2 (0.54) | HRH4CHEK1HRH3HRH2SMN1; SMN2 | |
| SCHEMBL564552 | 0.78 | HRH4 (0.50) | HRH4P4HTMHRH3HRH1 | |
| SCHEMBL2075565 | 0.78 | HRH4 (0.52) | HRH4P4HTMHRH3HRH1MAP4K4 | |
| SCHEMBL2074070 | 0.78 | HRH4 (0.56) | HRH4P4HTMHRH3SMN1; SMN2 | |
| SCHEMBL1773336 | 0.78 | HRH4 (0.68) | HRH4CHEK1CHEK2HRH3HRH1 | |
| SCHEMBL2088712 | 0.77 | HRH4 (0.62) | HRH4HRH3KDRHRH2 | |
| SCHEMBL2076114 | 0.77 | HRH4 (0.54) | HRH4P4HTMHRH3HRH1MAP4K4 | |
| SCHEMBL2076138 | 0.76 | HRH4 (0.54) | HRH4P4HTMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265602-B1 | SUBSTITUTED DIHYDROPYRAZOLONES AS INHIBITORS OF HIF-PROLYL-4-HYDROXYLASES | BAYER IP GMBH (DE) | 2015-04-08 | — | — | EP | disclosed |
| CN-102015685-B | Substituted dihydropyrazolones as HIF-prolyl-4-hydroxylase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-15 | — | — | CN | disclosed |
| US-20140038938-A1 | Substituted dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038938-A1 | Substituted dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-8580778-B2 | Substituted dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580778-B2 | Substituted dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580778-B2 | Substituted dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20120035151-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | BAYER HARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20120035151-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | BAYER HARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20120035151-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | BAYER HARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8067407-B2 | Substituted dihydropyrazolones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-29 | — | — | US | disclosed |
| US-8067407-B2 | Substituted dihydropyrazolones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-29 | — | — | US | disclosed |
| US-8067407-B2 | Substituted dihydropyrazolones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-29 | — | — | US | disclosed |
| CN-102015685-A | Substituted dihydropyrazolones as HIF-prolyl-4-hydroxylase inhibitors | BAYER SCHERING PHARMA AG | 2011-04-13 | — | — | CN | disclosed |
| EP-2265602-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AS INHIBITORS OF HIF-PROLYL-4-HYDROXYLASES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-12-29 | — | — | EP | disclosed |
| US-20090269420-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090269420-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090269420-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | US | disclosed |
| WO-2009129945-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AS INHIBITORS OF HIF-PROLYL-4-HYDROXYLASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009129945-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AS INHIBITORS OF HIF-PROLYL-4-HYDROXYLASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038938-A1 | Substituted dihydropyrazolones and their use | GLS, ATP6V1B1, PFKP | HRH4 1077/4885P4HTM 685/4885CHEK1 1972/4885 |
| US-20090269420-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | GLS, ATP6V1B1, PFKP | HRH4 1077/4885P4HTM 685/4885CHEK1 1972/4885 |
| US-20120035151-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | GLS, ATP6V1B1, PFKP | HRH4 1077/4885P4HTM 685/4885CHEK1 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.